Uricase and other novel agents for the management of patients with treatment-failure gout.

Journal Article (Journal Article;Review)

Successful management of chronic gout depends on reducing body pools of urate. The benchmark of success is to maintain serum urate levels at less than 6 mg/dL using therapies such as probenecid or allopurinol. In a subset of patients with gout, these medications fail to achieve this benchmark, resulting in ongoing signs and symptoms characteristic of treatment-failure gout. Potential therapies now in clinical development show promise for treating this refractory patient population. In this article, we review the clinical characteristics associated with treatment-failure gout and discuss recent data from clinical trials of febuxostat and uricase.

Full Text

Duke Authors

Cited Authors

  • Sundy, JS; Hershfield, MS

Published Date

  • June 2007

Published In

Volume / Issue

  • 9 / 3

Start / End Page

  • 258 - 264

PubMed ID

  • 17531181

International Standard Serial Number (ISSN)

  • 1523-3774

Digital Object Identifier (DOI)

  • 10.1007/s11926-007-0041-y


  • eng

Conference Location

  • United States